Varex Imaging Corporation designs and manufactures X-ray imaging components. The company operates in two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components comprising X-ray tubes, digital detectors, high voltage connectors, image-processing software and workstations, 3D reconstruction and computer-aided diagnostic software, collimators, automatic exposure control devices, generators, heat exchangers, ionization chambers, and buckys (a component of X-ray units that holds X-ray film cassettes). This segment's products are used in a range of applications, including radiographic and fluoroscopic imaging, mammography, computed tomography, radiation therapy, oncology, CT, cardiac, surgery, dental, computer-aided detection, and other diagnostic radiography uses. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital detectors, and high voltage connectors for use in security and industrial inspection applications, such as airport security, cargo screening at ports and borders, and nondestructive testing and examination in various applications. Varex Imaging Corporation sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was founded in 2016 and is based in Salt Lake City, Utah.
IPO Year:
Exchange: NASDAQ
Website: vareximaging.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/23/2024 | $21.00 | Buy | B. Riley Securities |
10/12/2022 | $24.00 | Hold | Jefferies |
SC 13G - Varex Imaging Corp (0001681622) (Subject)
SC 13G - Varex Imaging Corp (0001681622) (Subject)
SC 13G/A - Varex Imaging Corp (0001681622) (Subject)
SC 13G/A - Varex Imaging Corp (0001681622) (Subject)
SC 13G - Varex Imaging Corp (0001681622) (Subject)
SC 13G/A - Varex Imaging Corp (0001681622) (Subject)
SC 13G/A - Varex Imaging Corp (0001681622) (Subject)
SC 13G/A - Varex Imaging Corp (0001681622) (Subject)
SC 13G - Varex Imaging Corp (0001681622) (Subject)
SC 13G - Varex Imaging Corp (0001681622) (Subject)
Varex Imaging (NASDAQ:VREX) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.21 by 23.81 percent. This is a 38.46 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $206.200 million which beat the analyst consensus estimate of $205.150 million by 0.51 percent. This is a 9.64 percent decrease over sales of $228.200 million the same period last year.
Gainers Twist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out today. Jaguar Health (NASDAQ:JAGX) shares increased by 13.91% to $0.33. The company's market cap stands at $95.9 million. Tandem Diabetes Care (NASDAQ:TNDM) stock moved upwards by 12.25% to $41.04. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out today. Indaptus Therapeutics (NASDAQ:INDP) stock moved upwards by 11.29% to $2.26. The company's market cap stands at $19.2 million. Ardelyx (NASDAQ:ARDX) shares rose 11.02% to $7.54. Th
OutlookThe following guidance is provided for the second quarter of fiscal year 2024:Revenues are expected to be between $195 million and $215 millionNon-GAAP net earnings per diluted share is expected to be between $0.10 and $0.30Guidance for the company's net earnings per diluted share is provided on a non-GAAP basis only. This non-GAAP financial measure is forward-looking, and the company is unable to provide a meaningful or accurate reconciliation to a GAAP forecast of net earnings per diluted share without unreasonable effort due to certain of these reconciling items being uncertain, out of our control, and the amount and timing of these items being unable to be reasonably predicted. Th
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 27.9% to $0.37 during Tuesday's after-market session. The company's market cap stands at $5.6 million. DMK Pharmaceuticals (NASDAQ:DMK) stock moved upwards by 22.84% to $0.28. The company's market cap stands at $2.8 million. Mira Pharmaceuticals (NASDAQ:MIRA) stock rose 11.6% to $1.25. The company's market cap stands at $18.4 million. Vicarious Surgical (NYSE:RBOT) shares increased by 5.4% to $0.43. The company's market cap stands at $74.7 million. Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 4.97% to $0.77. The company's market cap stands at $13.7 million. Galecto (NASDAQ:GLTO) stock moved upwards by 4.82% to $0.6
Varex Imaging (NASDAQ:VREX) reported its Q1 earnings results on Tuesday, February 6, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Varex Imaging missed estimated earnings by 45.45%, reporting an EPS of $0.06 versus an estimate of $0.11. Revenue was down $15.60 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.1 which was followed by a 0.82% drop in the share price the next day. Here's a look at Varex Imaging's past performance: Quarter Q4 2023 Q3 2023 Q2 2023 Q1 2023 EPS Estimate 0.35 0.33 0.18 0.20 EPS Actual 0.45 0.37 0.26 0.21 Revenue Estimate 232.33M 229.90M 215.13M 205.35M Rev
Varex Imaging (NASDAQ:VREX) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.11 by 45.45 percent. This is a 71.43 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $190.00 million which beat the analyst consensus estimate of $187.97 million by 1.08 percent. This is a 7.59 percent decrease over sales of $205.60 million the same period last year.
B. Riley Securities initiated coverage of Varex Imaging with a rating of Buy and set a new price target of $21.00
Jefferies initiated coverage of Varex Imaging with a rating of Hold and set a new price target of $24.00
Oppenheimer upgraded Varex Imaging from Market Perform to Outperform and set a new price target of $35.50
Oppenheimer initiated coverage of Varex Imaging with a rating of Neutral and set a new price target of $35.50
Oppenheimer upgraded Varex Imaging from Perform to Outperform and set a new price target of $41.00
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the third quarter of fiscal year 2024. 3QFY24 Summary Revenues $209 million GAAP gross margin 32% | Non-GAAP gross margin* 32% GAAP operating margin 4% | Non-GAAP operating margin* 7% GAAP net earnings $0.03 per diluted share | Non-GAAP net earnings* $0.14 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated, "Revenue in the third quarter of fiscal 2024 came in as expected, driven primarily by continued strength in our cargo inspection business, which drove a 6% year-over-year increase in our Industrial segment." Varex's revenu
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2024 following the close of regular trading on Thursday, August 1, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from August 1st through
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the second quarter of fiscal year 2024. 2QFY24 Summary Revenues $206 million GAAP gross margin 32% | Non-GAAP gross margin* 33% GAAP operating margin 4% | Non-GAAP operating margin* 6% GAAP net earnings $0.03 per diluted share | Non-GAAP net earnings* $0.16 per diluted share Cash flow from operations was $3 million "Revenue of $206 million in the second quarter was in line with guidance, but down year-over-year primarily due to lower sales to our customers in China," said Sunny Sanyal, Chief Executive Officer of Varex. "Sales in the first half of fiscal 2024 were as expected, but
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2024 following the close of regular trading on Thursday, May 2, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from May 2nd through May
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the first quarter of fiscal year 2024. 1QFY24 Summary Revenues $190 million GAAP gross margin 30% | Non-GAAP gross margin* 31% GAAP operating margin 2% | Non-GAAP operating margin* 5% GAAP net loss $0.01 per diluted share | Non-GAAP net earnings* $0.06 per diluted share Cash flow from operations was $10 million "Revenue of $190 million in the first quarter of fiscal 2024, was at the mid-point of our guidance, however unfavorable mix in both the Medical and Industrial segments impacted profitability." said Sunny Sanyal, Chief Executive Officer of Varex. Varex's revenue of $190 mi
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the first quarter of fiscal year 2024 following the close of regular trading on Tuesday, February 6, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from February 6th thro
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the fourth quarter of fiscal year 2023. Q4 FY23 Summary Revenues of $227 million GAAP gross margin 34% | Non-GAAP gross margin* 36% GAAP operating expense $54 million | Non-GAAP operating expense* $51 million GAAP operating margin 11% | Non-GAAP operating margin* 13% GAAP net income $0.66 per diluted share | Non-GAAP net income* $0.45 per diluted share Cash flow from operations $47 million FY23 Summary Record revenues of $893 million GAAP gross margin 32% | Non-GAAP gross margin* 33% GAAP operating expense $213 million | Non-GAAP operating expense* $199 million GAAP
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the fourth quarter and full fiscal year 2023 following the close of regular trading on Tuesday, November 14, 2023. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from November
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the third quarter of fiscal year 2023. 3QFY23 Summary Revenues $232 million GAAP gross margin 33% | Non-GAAP gross margin* 34% GAAP operating margin 10% | Non-GAAP operating margin* 13% GAAP net earnings $0.21 per diluted share | Non-GAAP net earnings* $0.37 per diluted share Cash flow from operations $38 million "We are pleased to report another solid quarter, with revenues reaching $232 million in the third quarter of fiscal 2023, a new quarterly record for Varex, and non-GAAP gross margin of 34% exceeding our expectations. These results were helped by the continued strength in
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2023 following the close of regular trading on Tuesday, August 1, 2023. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at https://www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from August 1st
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
4 - Varex Imaging Corp (0001681622) (Issuer)
8-K - Varex Imaging Corp (0001681622) (Filer)
10-Q - Varex Imaging Corp (0001681622) (Filer)
8-K - Varex Imaging Corp (0001681622) (Filer)
SD - Varex Imaging Corp (0001681622) (Filer)
10-Q - Varex Imaging Corp (0001681622) (Filer)
8-K - Varex Imaging Corp (0001681622) (Filer)
8-K - Varex Imaging Corp (0001681622) (Filer)
S-8 - Varex Imaging Corp (0001681622) (Filer)
8-K - Varex Imaging Corp (0001681622) (Filer)
10-Q - Varex Imaging Corp (0001681622) (Filer)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the third quarter of fiscal year 2024. 3QFY24 Summary Revenues $209 million GAAP gross margin 32% | Non-GAAP gross margin* 32% GAAP operating margin 4% | Non-GAAP operating margin* 7% GAAP net earnings $0.03 per diluted share | Non-GAAP net earnings* $0.14 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated, "Revenue in the third quarter of fiscal 2024 came in as expected, driven primarily by continued strength in our cargo inspection business, which drove a 6% year-over-year increase in our Industrial segment." Varex's revenu
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the third quarter of fiscal year 2024 following the close of regular trading on Thursday, August 1, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from August 1st through
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Conference taking place Wednesday and Thursday, June 12-13, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.Presentation Schedule*All Times EDTWednesday, June 12, 2024 (Day 1)8:30-9:00**********InfuSystem Holdings Inc. (INFU)*****9:15-9:45*****ECD Automotive (ECDA)Lifeward [ReWalk Robotics] (LFWD)*****10:00-10:30Unisys Corporation (UIS)*****Myomo, Inc (MYO)Drilling Tools International Corp. (DTI)10:45-11:15American Softwar
Varex Imaging Corporation (NASDAQ:VREX) announced today that management is scheduled to participate in the following upcoming investor conferences. Jefferies Global Healthcare Conference in New York – June 6, 2024 at 9:00am ET Goldman Sachs 45th Annual Global Healthcare Conference in Miami – June 10, 2024 (1x1 only) Sidoti June 2024 Virtual Small Cap Conference – June 13, 2024 at 10:45am ET These events can be accessed at the Varex Imaging website: www.vareximaging.com/news on the dates and times listed above. About Varex Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and o
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the second quarter of fiscal year 2024. 2QFY24 Summary Revenues $206 million GAAP gross margin 32% | Non-GAAP gross margin* 33% GAAP operating margin 4% | Non-GAAP operating margin* 6% GAAP net earnings $0.03 per diluted share | Non-GAAP net earnings* $0.16 per diluted share Cash flow from operations was $3 million "Revenue of $206 million in the second quarter was in line with guidance, but down year-over-year primarily due to lower sales to our customers in China," said Sunny Sanyal, Chief Executive Officer of Varex. "Sales in the first half of fiscal 2024 were as expected, but
Varex Imaging Corporation (NASDAQ:VREX) today announced that it will report unaudited financial results for the second quarter of fiscal year 2024 following the close of regular trading on Thursday, May 2, 2024. The earnings news release will be followed by a conference call at 3:00 pm Mountain Time that day. This call will be webcast live and can be accessed at the company's website at www.vareximaging.com/investor-relations/. Investors can also access this conference call at 877-524-8416 from anywhere in the U.S. or 412-902-1028 from non-U.S. locations. The webcast of this call will be archived on the company's website and a replay of the call will be available from May 2nd through May
Varex Imaging Corporation (NASDAQ:VREX) today announced it has entered into a senior secured revolving credit agreement (the "RLOC Facility") for an initial aggregate principal amount of up to $155 million. Zions Bancorporation, N.A. ("Zions") acted as lead arranger and bookrunner for the new RLOC Facility. Simultaneously, Varex terminated its existing senior secured asset-based revolving credit agreement. "We are pleased to have successfully closed the revolving credit facility," said Sam Maheshwari, Chief Financial Officer of Varex Imaging Corporation. "The additional liquidity provides funds to address working capital and other general corporate purposes, including potential repayment
Varex Imaging Corporation (NASDAQ:VREX) announced today that management is scheduled to present at the Oppenheimer 34th Annual Healthcare MedTech & Services Virtual Conference. Management will be participating in a fireside chat on Tuesday, March 12, 2024 at 1:20pm EDT. The webcast can be accessed here or on Varex's website at www.vareximaging.com/news. About Varex Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex's products are used in medical i
Varex Imaging Corporation (NASDAQ:VREX) today announced its unaudited financial results for the first quarter of fiscal year 2024. 1QFY24 Summary Revenues $190 million GAAP gross margin 30% | Non-GAAP gross margin* 31% GAAP operating margin 2% | Non-GAAP operating margin* 5% GAAP net loss $0.01 per diluted share | Non-GAAP net earnings* $0.06 per diluted share Cash flow from operations was $10 million "Revenue of $190 million in the first quarter of fiscal 2024, was at the mid-point of our guidance, however unfavorable mix in both the Medical and Industrial segments impacted profitability." said Sunny Sanyal, Chief Executive Officer of Varex. Varex's revenue of $190 mi